# Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

> **NCT07589517** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 48 (estimated)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Adenocarcinoma
- Unresectable Colorectal Cancer

## Interventions

- **BIOLOGICAL:** EB-DUO-CAR-NK-CEA/GCC
- **DRUG:** Lymphodepletion

## Key facts

- **NCT ID:** NCT07589517
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-03-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07589517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07589517, "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07589517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*